medigraphic.com

2004, Number 6

<< Back Next >>

Cir Cir 2004; 72 (6)

Simultaneous evaluation of the myocardial perfusion and contraction for cardiac scintigraphy synchronized to the electrocardiogram for the differential diagnosis of dilated cardiomyopathy and the ischemic ventricular damage

Ortega-Ramírez JA, Valenzuela-Flores AG, Gaxiola-Alcántar A, Estrada-Alcántara H, Pérez-Campos JP

Language: Spanish
References: 50
Page: 471-478
PDF size: 73.98 Kb.


ABSTRACT

Objective: We evaluated the precision of the perfusion and ventricular function through cardiac scintigraphy 99mTc-MIBI SPECT synchronized to the electrocardiogram to differentiate the ventricular damage of ischemic origin from the dilated cardiomyopathy. Material and methods: Thirty patients with myocardial damage with ejection fraction = 30% were included. We analyzed the prognostic value of clinical, angiographic, and 99mTc-MIBI SPECT variables. Results: We studied 30 patients with myocardial damage, 26 men (86.7%) and 4 women (13.3%), with an average age of 45.7 ± 9.3 years. The diagnosis established by cardiac catheterization was dilated cardiomyopathy in 17 patients (56.6%) and 13 with ischemic cardiomyopathy (43.4%). The study by cardiac scintigraphy 99mTc-MIBI SPECT synchronized to the electrocardiogram established the diagnosis of dilated cardiomyopathy in 18 patients, with a sensitivity of 100% and specificity of 92%. The predictive positive value was 100% and the predictive negative value 94.4%. Conclusions: Cardiac scintigraphy 99mTc-MIBI SPECT synchronized to the electrocardiogram differs in the etiology of the myocardial damage produced by dilated cardiomyopathy from that of ischemic origin in a noninvasive way and with high sensitivity and specificity.


REFERENCES

  1. US Department of Health and Human Services and the National Lung, Heart and Blood Institute. Morbidity and mortality chart book in cardiovascular, lung and blood disease. Washington DC: Government Printing Office; 1990; Series: 25.

  2. Gónzalez CA, Pérez BJ, Nieto CM, Vázquez CA, Gaytan FE. Importancia de las enfermedades crónicas degenerativas dentro del panorama epidemiológico actual de México. Salud Publica Mex 1986; 28:3-13.

  3. Cools SJ, Vrints CJ, Snoeck JP. Angiographic coronary artery lesion morphology and pathogenic mechanisms of myocardial ischemia in stable and unstable coronary artery disease. Acta Cardiol 1992;47:13-30.

  4. Chamnless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. Circulation 1997;96:3849-3859.

  5. Hheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary disease. Circulation 1998;97:282-289.

  6. Iskandrian AS, Heo J, Nguyen T. Assessment of myocardial viability. Am Heart J 1990;120:1012-1014.

  7. Cerqueira MD, Jacobson AF. Assessment of myocardial viability with SPECT and PET imaging. Am J Roentgenol 1989;153:477-483.

  8. Antozzi C, Zeviani M. Cardiomyopathies in disorders of oxidative metabolism. Cardiovasc Res 1997;35(2):184-199.

  9. Johnson RA, Palacios I. Dilated cardiomyopathies of the adult. I. N Engl J Med 1982;307:1051-1058.

  10. Pasternac A, Noble J, Steulens Y, Elie R, Henschke C, Bourassa MG. Pathophysioloy of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982;65:778-789.

  11. Oakley CM, Gravanis MB, Ansari AA. The cardiomyopathies. In: Granavis MB, ed. Cardiovascular disorders. Pathogenesis and pathophysiology. St. Louis, MO: Mosby;1993.

  12. Felker MG. Shaw L, O’Connor C. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210–218.

  13. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.

  14. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction evidence for the hibernating myocardium. J Am Coll Cardiol 1986;8:1467-1470.

  15. Kleikamp G, Maleszka A, Reiss N, Stuttgen B, Korfer R. Determinants of mid- and long-term results in patients after surgical revascularization for ischemic cardiomyopathy Ann Thorac Surg 2003;75: 1406-1413.

  16. Saltissi S, Hockings B, Croft DN, Webb-People MM. Thallium 201 myocardial imaging in patients with dilated and ischemic cardiomyopathy. Br Heart J 1981;46:290-295.

  17. Pachinger O, Ogris E, Sochor H, Probst P, Zasmeta H, Kaindi F. Radionuclide assessment of cardiac performance and myocardial perfusion in congestive cardiomyopathies. Clin Cardiol 1979;2:264-271.

  18. Iskandrian AS, Helfeld H, Lemlek J. Differentiation between primary dilated cardiomyopathy and ischemic cardiomyopathy based on right ventricular performance. Am Heart J 1992;123:768-773.

  19. Iskandrian AS, Hakki AH, Kane S. Resting thallium 201 myocardial perfusion patterns in patients with severe left ventricular dysfunction: differences between patients with primary cardiomyopathy, chronic coronary artery disease, or acute myocardial infarction. Am Heart J 1986;111:760-767.

  20. Dunn RF, Uren RF, Sadick N, Bautovich G, McLaughlin A, Hiroes M, Kelly DT. Comparison of thallium 201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 1982;66:804-810.

  21. Eichhorn EJ, Kosinski EJ, Lewis SM, Hill TC, Emmond LH, Leland OS. Usefulness of dipiridamol-thallium 201 perfusion scanning for distinguishing ischemic from nonischemic cardiomyopathy. Am J Cardiol 1988;62:945-951.

  22. Pace L, Perrone Filardi P, Mainenti P, Cuocolo A, Vezzuto P, Prastaro M, et al. Identification of viable myocardium in patients with chronic coronary artery disease using rest-redistribution thallium 201 tomography: optimal image analysis. J Nucl Med 1998;39:1869-1874.

  23. Eisenberg JD, Sobel BE, Geltman EM. Differentiation of ischemic from nonischemic cardiomyopathy with positron emission tomography. Am J Cardiol 1982;59:1410-1414.

  24. Budoff J, Shavelle DM, Lamont D, Kim T, Akinwale P, Kennedy JM, et al. Heart failure. Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. JACC 1998;32:1173-1178.

  25. Marin-Neto JA, Dilsizian V, Arrighi JA, Perrone-Filardi P, Bacharach SL, Bonow RO. Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. J Am Coll Cardiol 1998;82:1001-1007.

  26. Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U, Mehrabi M, et al. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium 201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol 1998;32:1701-1708.

  27. Lapu-Bula R, Robert A, De Kock M, D’Hondt AM, Detry, JM, Melin J, et al. Risk stratification in patients with dilated cardiomyopathy: contribution of Doppler-derived left ventricular filling. Am J Cardiol 1998;82:779-785.

  28. Iskandrian A, Hakki AH, Kane S. Resting thallium 201 myocardial perfusion patterns in patients with severe left ventricular dysfunction: differences between patients with primary cardiomyopathy, chronic coronary disease, or acute myocardial infarction. Am Heart J 1986;111:760-767.

  29. DePuey EG, Nichols K, Dobrinsky C. Left ventricular ejection fraction assessed from gated technetium-99m-sestamibi SPECT. J Nucl Med 1993;34:1871-1876.

  30. Yang KT, Chen HD. Evaluation of global and regional left ventricular function using technetium-99m sestamibi ECG-gated single photon emission tomography. Eur J Nucl Med 1998;25:515-521.

  31. Khattar RS, Senior R, Lahiri A. Assessment of myocardial perfusion and contractile function by inotropic stress Tc-99m Sestamibi SPECT imaging and echocardiography for optimal detection of multivessel coronary artery disease. J Nucl Med 1998;79:274-280.

  32. Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe ER, Gross M, Fig L, Schwaiger M. Positron emission tomography detects evidence of viability in rest technetium-99m Sestamibi defects. J Am Coll Cardiol 1994;23:92-98.

  33. Soufer R, Dey HM, Ng CK, Zaret BL. Comparison of sestamibi single photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. Am J Cardiol 1995;75:1214-1219.

  34. García EV, Cooke CD, Van Train KF, Folks R, Pfeifer K, DePuey EG, et al. Technical aspects of myocardial SPECT imaging with technetium-99m sestamibi. Am J Cardiol 1990;66:23E-31E.

  35. Marcasa C, Marzullo P, Parodi O, Sambuceti G, Abatte A. A new method for noninvasive quantification of segmental myocardial wall thickening using technetium-99m 2-methoxy-isobutyl-isonitrile scintigraphy results in normal subjects. J Nucl Med 1990; 31:173-177.

  36. Mannting F, Morgan Mannting MG. Gated SPECT with technetium-99m sestamibi for assessment of myocardial perfusion abnormalities. J Nucl Med 1993;34:601-608.

  37. Williams KA, Taillon LA. Left ventricular function in patients with coronary artery disease by gated topographic myocardial perfusion images. Comparison with assessment by contrast ventriculography and first pass radionuclide angiography. J Am Coll Cardiol 1996;27: 173-181.

  38. Schwarz ER, Pollick, C, Dow J, Patterson M, Birnbaum Y, Kloner RA. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res 1998;39:216-223.

  39. Van Train KF, Garcia EV, Maddahi J. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms. J Nucl Med 1994;35:609-8s.

  40. Wackers FJ. Nuclear Cardiology. The basics: How to set up and maintain a laboratory. Clifton, NJ: Humana Press;2004.

  41. Heller G. Nuclear cardiology. Practical applications. New York: McGraw-Hill;2004.

  42. Vásquez JP, Iglesias LM, Vázquez Rey E, Calviño S, Vázquez RJ, Fábregas R, Salgado J, et al. Ecocardiografía de ejercicio para diferenciar la miocardiopatía dilatada de la disfunción ventricular por cardiopatía isquémica. Rev Esp Cardiol 2003;56:57-64.

  43. Pérez-Paredes M, Carnero A, Diego M, Jiménez D, Ruiz-Ros JA, González M, et al. Predictores de reserva contráctil miocárdica en pacientes con miocardiopatía dilatada no isquémica. Estudio mediante ecocardiografía de estrés con dobutamina. Rev Esp Cardiol 2003; 56:995-1000.

  44. Álvarez LM, Alcalá LJ, Baún MO, Tercedor SL, Ramírez HJ, Rodríguez PL, et al. Utilidad del índice Doppler DP/DT en la evaluación de la disfunción sistólica ventricular izquierda. Rev Esp Cardiol 1997;50:105-110.

  45. Pauschinger M, Doerner A, Remppis A, Tannhauser R, Kuhl U, Schultheiss HP. Differential myocardial abundance of collagen type I and type III mRNA in dilated cardiomyopathy: effects of myocardial inflammation. Cardiovasc Res 1998; 37:123-129.

  46. Yamaguchi A, Ino T, Adachi H, Murata S, Kamio H, Okada M, et al. Left ventricular volume predicts postoperative course in patients with ischemic cardiomyopathy. Ann Thorac Surg 1998;65:434-438.

  47. Danias P, Ahlberg AW, Clark III, BA, Messineo F, Levine M, McGill C, et al. Combined assessment of myocardial perfusion and left ventricular function with exercise technetium-99m Sestamibi gated single-photon emission computed tomography can differentiate between ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 1998;82:1253-1258.

  48. San Martin MA, García A, Rodríguez FJ, Terol I. Autoinmunidad y miocardiopatía dilatada: situación actual y perspectivas Rev Esp Cardiol 2002;55:514-524.

  49. Cheng T. Ischemic cardiomyopathy: a historical note. JACC 2002;39: 1563-1565.

  50. Lytle BW. The role of coronary revascularization in the treatment of ischemic cardiomyopathy. Ann Thorac Surg 2003;75:S2-S5.




2020     |     www.medigraphic.com